Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7057627 | 0.90 | CNR2 (0.49) | CNR2HTR7TSHRCNR1 | |
| SCHEMBL13563353 | 0.86 | KDM4E (0.49) | CNR2HTR7LMNA | |
| SCHEMBL7059044 | 0.84 | CNR2 (0.47) | CNR2HTR7TSHRLMNACNR1 | |
| SCHEMBL7059035 | 0.84 | CNR2 (0.47) | CNR2HTR7TSHRLMNACNR1 | |
| SCHEMBL13354921 | 0.83 | CNR2 (0.53) | CNR2HTR7TSHRLMNACNR1 | |
| SCHEMBL11811721 | 0.82 | APEX1 (0.50) | TSHRLMNAPOLBGAA | |
| SCHEMBL13007407 | 0.79 | CNR2 (0.50) | CNR2HTR7TSHRLMNACNR1 | |
| SCHEMBL13322667 | 0.78 | CNR2 (0.54) | CNR2HTR7LMNACNR1 | |
| SCHEMBL14261219 | 0.77 | CNR2 (0.64) | CNR2HTR7TSHRLMNACNR1 | |
| SCHEMBL7272865 | 0.77 | CNR2 (0.49) | CNR2HTR7CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322622-B1 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | SPROUT PHARMACEUTICALS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1322622-A2 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6521623-B1 | 1-(2-(4-(3-chlorophenyl)-1-piperazinyl)ethyl)-3-(2-hydroxyethyl) -1,3-dihydro-2H-benzimidazol-2-one for example; treating anxiety disorders and psychological disorders, brain injuries | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20030027823-A1 | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | Salix Pharmaceuticals, Ltd | 2003-02-06 | — | — | US | disclosed |
| WO-2002024661-A2 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027823-A1 | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | OPRM1, HTR2C, HTR3C | CNR2 54/4885HTR7 19/4885TSHR 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.